MOSCOW, February 2. /TASS/. The Gamaleya Research Institute of Epidemiology and Microbiology, the developer of Sputnik V, expects the duration of immunity provided by the vaccine will be over two years, Alexander Gintsburg, head of the center, told a press conference on Tuesday.
"We have a strong hope, which is confirmed by the already obtained results of clinical trials, that the vaccine will be able to provide immunity not for several months, or even a year, but for at least two years or more, which is the subject of our further research, of course," he said.
Gintsburg noted that the adenovirus platform, the Sputnik V vaccine is based on, has once again showed its future outlook, reliability and safety.
Earlier, the Lancet, one of the world's oldest and most respected medical journals, published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine’s high efficacy and safety. In particular, the vaccine showed strong efficacy of 91.6% and among the volunteers older than 60 years the efficacy was 91.8%. The level of virus neutralizing antibodies of volunteers vaccinated with Sputnik V turned to be 1.3-1.5 times higher than the level of antibodies of patients who recovered from COVID-19.